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ABSTRACT
Introduction: Many inflammatory conditions,
such as asthma, show circadian symptoms that
are worse at night. Delayed-release prednisone
was developed for bedtime administration to
optimize inhibition of nocturnally elevated
pro-inflammatory cytokines. A
proof-of-concept study was undertaken to
examine the impact of delayed-release
prednisone on nocturnal awakenings in
patients with asthma requiring treatment with
oral steroids.
Methods: In this single-center, open-label
study, patients receiving long-term treatment
with conventional prednisone administered at
08:00 h were switched to 4 weeks of treatment
with the same dose of delayed-release
prednisone given at 22:00 h. The primary
efficacy endpoint was the change in number
of nocturnal awakenings during the final
2 weeks of each treatment phase.
Results: Seven patients received treatment with
delayed-release prednisone. Mean nocturnal
awakenings because of asthma decreased from
10.0 ± 5.45 with conventional prednisone to
2.1 ± 4.41 with delayed-release prednisone, a
mean reduction of -7.9 ± 6.07 (82.7%
reduction). Delayed-release prednisone was
generally well tolerated, and there were no
unexpected safety findings.
Conclusions: Although the size of the efficacy
population was too small to detect any
statistically significant changes in nocturnal
asthma control, this proof-of-concept study
suggests that nighttime administration of
delayed-release prednisone provides better
asthma symptom control compared with
morning administration of conventional
prednisone.
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INTRODUCTION
More than 60 years after their first clinical use,
corticosteroids still form the mainstay of
treatment for inflammatory conditions [1, 2].
With awareness of potential safety and
tolerability issues arising from systemic
exposure, topical corticosteroid preparations
were developed, including inhaled
formulations for use in inflammatory
respiratory conditions (e.g., asthma). In other
inflammatory conditions (e.g., rheumatoid
arthritis or polymyalgia rheumatica), the
chronic systemic nature or inaccessible
location of the affected site precludes routine
topical treatment and, therefore,
administration of corticosteroids remains
predominantly via the oral route. The need to
improve the benefit:risk ratio for these patients
continues to drive the development of this
important class of treatment.
A common feature of many inflammatory
conditions, including asthma, is the circadian
pattern of symptoms [3, 4]. Recognition of this
characteristic in rheumatoid arthritis prompted
development of an oral formulation of
prednisone that can be taken at bedtime, but
releases the active ingredient approximately 4 h
later, at the appropriate time to inhibit the
nocturnal peak of pro-inflammatory cytokines
that are associated with morning symptoms [5,
6]. In patients with rheumatoid arthritis,
delayed-release prednisone reduces morning
stiffness significantly more than the same dose
of conventional prednisone (3–10 mg/day)
taken in the morning, with benefit sustained
over 12 months of treatment [7, 8]. Although in
Europe, it is predominantly used to treat
rheumatoid arthritis, in the USA and other
countries the common nature of many
inflammatory conditions is recognized in the
approved indication of delayed-release
prednisone as an anti-inflammatory or
immunosuppressive agent for a range of
conditions, including allergic and respiratory
conditions.
The circadian nature of asthma symptoms is
widely recognized by clinicians and patients alike.
The involvement of clock genes located centrally
and in the lung has been reported [4]. In the UK,
37% of patients with asthma reported frequent
nighttime symptoms and in a large Europe-wide
survey of patients with asthma, 54.5% reported
one or more nights during the previous week with
waking because of asthma [9, 10]. Nocturnal
symptoms are usually indicative of poor asthma
control [11]. Although adjustment of inhaled
therapy may be sufficient for most patients,
frequent nocturnal asthma symptoms are
characteristic of severe persistent asthma that is
difficult to treat [11, 12]. Patients with these
symptoms usually require long-term treatment
with oral corticosteroids in addition to inhaled
therapy. In the USA, an estimated 4% of patients
with asthma receive treatment with oral
corticosteroids for at least 6 months,
predominantly at doses up to 10 mg per day [13].
As in rheumatoid arthritis, there might be
room to improve the optimal or preferred
delivery of glucocorticoids and possibly
improve the therapeutic ratio in patients with
severe persistent nocturnal asthma who require
longer term therapy. Delayed-release
prednisone (also known as modified-release
prednisone) once released in the
gastrointestinal track behaves exactly like
conventional (immediate-release prednisone)
[5]. When taken orally at bedtime, prednisone
peaks in the plasma approximately 6 h later [5].
This corresponds to the time when the
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hypothalamic–pituitary–adrenal (HPA) axis is
most active, and is the preferred time to deliver
glucocorticoid therapy from both an efficacy
(i.e., most heightened inflammatory period)
and a safety perspective (least likely to
dampen the HPA axis long term) [3, 5, 6]. As
we report here, the Modified-Release Prednisone
for Treatment of Nocturnal Asthma (MONA)
study was an exploratory proof-of-concept
study to evaluate the impact on nocturnal
symptoms of a switch from conventionally
administered immediate-release prednisone to




Patients included in the study were aged at least
18 years with a diagnosis of severe persistent
asthma based on the American Thoracic Society
(ATS) criteria [14], following monitoring for at
least 18 months. All patients required
continued treatment with oral corticosteroids
for at least 12 months, in addition to standard
therapy (high doses of inhaled steroids plus
long-acting beta-2 agonist), and all patients had
frequent nocturnal symptoms (at least three
nocturnal awakenings because of asthma during
the final screening week). Patients with hospital
admission for asthma and/or lower airway
infection in the 4 weeks before study entry
were excluded from the study.
Study Design
This was a single-center, open-label, Phase IIa,
sequential, single-treatment proof-of-concept
study performed between July 2008 and May
2010. Eligible patients received treatment with
conventional prednisone during a 4-week
period (Weeks 0–4; treatment period 1) before
switching to the same dose of delayed-release
prednisone for 4 weeks (Weeks 4–8; treatment
period 2). Conventional prednisone was
administered at 08:00 h ± 30 min and
delayed-release prednisone was administered at
22:00 h ± 30 min.
Assessments
Scheduled visits occurred at Week 0 and every
2 weeks to week 8. The primary efficacy
endpoint was the change in the mean number
of nocturnal awakenings during the final
2 weeks of each treatment phase. Secondary
endpoints included changes in respiratory
function measured by morning and evening
peak expiratory flow (PEF), forced expiratory
volume in 1 s (FEV1), and forced vital capacity
(FVC) at the end of each treatment period. The
impact of asthma on patients was determined at
the end of each treatment period, using the
Asthma Control Questionnaire (ACQ) and
Asthma Quality of Life Questionnaire (AQLQ)
[15, 16]. For the ACQ (which assesses asthma
control over the previous week), a decrease in
score corresponds to an improvement in asthma
control [16]. For the AQLQ (which assesses the
impact of asthma on health-related quality of
life during the previous 2 weeks), an increase in
score corresponds to an improvement in quality
of life [15].
Safety
Safety and tolerability data were collected for all
patients. Safety assessments included physical
examination, vital signs, and laboratory and/or
biological data. All adverse events (AEs) were
recorded with information on their severity,
relation to study medication, duration, and
whether they were considered serious.
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Statistical Analysis
All analyses were descriptive. The study was not
designed or powered to detect statistical
differences in endpoints. The study aimed to
recruit a minimum of five and a maximum of 20
patients. The safety population comprised all
patients dispensed any study medication. The
efficacy population comprised all patients who
completed both treatment periods.
Compliance with Ethics Guidelines
The study was conducted in accordance with
the International Conference on
Harmonization Guidelines for Good Clinical
Practice and the Declaration of Helsinki. The
protocol was approved by the local ethics
committee/institutional review board, and all
patients provided informed written consent
prior to study-related procedures.
RESULTS
Study Population
Of 15 patients screened, a total of 12 patients
were eligible to enter treatment period 1,
receiving conventional prednisone; these
patients constituted the safety population.
During this period, five patients were
withdrawn; the remaining patients entered the
delayed-release prednisone treatment period
(treatment period 2) and completed the study
(efficacy population; Fig. 1). Patient
demographics are shown in Table 1. Previous
medical history in the study population
included surgical procedures in 11 patients
[mostly cesarean section or appendicectomy
(58%)], history of infection (58%),
gastrointestinal pregnancy or perinatal
conditions, reproductive or breast disorders,
respiratory disorders, vascular disorders, and
phlebitis, which occurred in two (16.7%)
patients each. Prednisone doses for the
patients completing the study ranged from
5 mg to 45 mg/day with a median dose of
20 mg/day both before and after switch to
delayed-release prednisone, indicating parity
in the doses between both study arms.
Efficacy
Following the switch to delayed-release
prednisone, the number of nocturnal
awakenings because of asthma decreased from
a mean (SD) of 10.0 ± 5.45 to 2.1 ± 4.41, a
Fig. 1 Study design and patient disposition
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mean reduction of -7.9 ± 6.07 and mean
relative reduction of -82.7% (Table 2). The
number of nocturnal awakenings was reduced
in six out of the seven patients (Fig. 2).
Improvements were also seen in other
measures of lung function (Table 3).






Mean ± SD 48.9 ± 14.4 46.1 ± 15.74
Median (range) 52.4 (22–68) 51.1 (22–63)
Female sex, N (%) 11 (91.7) 7 (100)
Body mass index (kg/m2, mean ± SD) 27.0 ± 5.96 27.0 ± 5.89
Never smoked, N (%) 8 (66.7) 5 (71.4)
Time since diagnosis of asthma (years)
Mean ± SD 26.2 ± 17.93 18.7 ± 13.56
Median (range) 20.7 (5–59) 15.6 (5–41)
Time since last asthma exacerbation (months)
Mean ± SD 19.9 ± 40.28 10.0 ± 12.29
Median (range) 6.1 (3–144) 6.0 (3–37)
Time since last hospital admission for asthma, years
Mean ± SD 4.4 ± 8.77 5.5 ± 11.62
Median (range) 1.6 (0.3–32) 1.2 (0.3–32)
Medication
Number of patients with at least one previous asthma medication other









Number of patients with glucocorticoid use 12 (100) 7 (100)
Equivalent daily prednisone dose
Mean mg dose 17.22 18.57
Median mg dose 20 20
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General asthma control, as assessed by the
ACQ, improved from a mean (SD) of 18.7 ± 3.30
in the final week of conventional prednisone
treatment to a mean (SD) of 11.4 ± 3.46 in the
final week of therapy with delayed-release
prednisone. Asthma-related quality of life
scores (as measured by the AQLQ) improved
from a mean (SD) of 130.9 ± 19.69 in the final
2 weeks of conventional prednisone treatment
to a mean (SD) of 162.2 ± 25.97 in the final
2 weeks of delayed-release prednisone
treatment. Improvements in these
patient-reported outcomes were seen in six out
of the seven patients (Fig. 3).
Table 2 Nocturnal awakenings










Mean (SD) 10.0 (5.45) 2.1 (4.41) -7.9 (6.07) -82.7 (36.88)
95% CI 5.0; 15.0 -1.9; 6.2 -13.5; -2.2 -116.8; -48.6
Median
(range)
12 (1 to 15) 0 (0 to 12) -10 (-14 to
0)
-100 (-100 to 0)
CI conﬁdence interval, SD standard deviation
16
Final 2 weeks of
conventional
prednisone


































Fig. 2 Patient response: nocturnal awakenings
Table 3 Measures of lung function










Morning PEF (L/min) 284.2 (108.51) 300.2 (89.65) 16.0 12.0
Evening PEF (L/min) 280.1 (74.75) 327.5 (97.11) 47.3 17.2
FEV1 (L) 2.05 (0.866) 2.09 (0.638) 0.04 9.2
FVC (L) 2.75 (0.912) 2.88 (0.779) 0.14 9.7
FEV1/Predicted* 77.2% 78.9%
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, PEF peak expiratory ﬂow, SD standard deviation
* FEV1 end of week 4/predicted for conventional prednisone and FEV1 end of week 4/predicted for delayed-release
prednisone, pre-bronchodilator
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Safety and Tolerability
Most AEs reported during the study were of
mild-to-moderate intensity and most were
respiratory disorders. During the first treatment
period (conventional prednisone), seven patients
(58.3%) experienced at least one AE, with one
considered serious (asthma exacerbation and
arterial thrombosis). The most common AEs
were reported in the Infections and Infestations
category (33%). None of the AEs are considered
related to study treatment. During the second
treatment period (delayed-release prednisone),
six patients (85.7%) experienced at least one AE,
none serious. The most common AEs reported
were in the Respiratory, Thoracic and Mediastinal
Disorders category (42.9%). In two patients, the
AEs (tremor and insomnia in one patient, and
insomnia in one patient) were considered related
to study treatment. There were no deaths or
life-threatening AEs associated with study
treatments. No clinically relevant changes in
hematological or biochemical parameters, or
vital signs were observed during the study.
DISCUSSION
Results from this small proof-of-concept study
suggest that patients requiring oral
corticosteroid treatments for severe nocturnal
asthma benefit from a switch to delayed-release
prednisone.
Nocturnal asthma is a variable exacerbation
of the underlying asthma condition associated
with increases in symptoms, need for
medication, and worsening of lung function.
These changes are related to sleep and/or
circadian events [17]. Studies in patients with
nocturnal asthma have demonstrated circadian
changes in circulating eosinophils numbers that
correlated with peak-flow variation [18, 19].
Fluctuating eosinophil inflammation was also
observed in bronchoalveolar lavage fluid and in
transbronchial biopsies of patients with asthma,
with greater magnitude of increase in those
with nocturnal symptoms [20, 21]. These data
suggest that circadian activation of
inflammatory cells has a pathogenic role in
the development of nighttime airflow
limitation. Therefore, as with other
inflammatory conditions with circadian
symptoms, an anti-inflammatory drug
targeting this nocturnal peak in airway
inflammation could show benefits over the
same treatment used at other times of the day.
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conventional
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Fig. 3 Patient-reported outcomes. a Asthma Control
Questionnaire (ACQ) scores; b asthma-related Quality
of Life Questionnaire (AQLQ) scores
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ago, although nocturnal corticosteroid
administration was not investigated [22]. The
impact on nocturnal asthma symptoms of
inhaled steroid administration time is unclear
[23]. In our proof-of-concept study,
delayed-release prednisone given at 22:00 h
was superior to conventional prednisone given
at 08:00 h. The improvement in asthma control
and nocturnal symptoms observed with
delayed-release prednisone might result from
the delivery of anti-inflammatory therapy at the
most appropriate time to inhibit
pathophysiological processes that result in
symptoms.
Delayed-release prednisone was generally
well tolerated, and there were no deaths or
life-threatening AEs. There were no
unexpected safety findings. These results are
consistent with those with rheumatoid
arthritis [7, 8, 24].
Although the size of the efficacy population
was too small to detect any statistically
significant changes, this proof-of-concept study
suggests that delayed-release prednisone provides
better asthma symptom control compared with
standard morning administration of
conventional prednisone. The limitations of an
small, open-label, nonrandomized study such as
this are well known and further study of
delayed-release prednisone in patients with
severe asthma is warranted to investigate
whether switching to this treatment from the
more conventional formulation improves
outcomes and potentially allows a reduction in
corticosteroid dose, as has been noted in the
treatment of rheumatoid arthritis [25].
CONCLUSION
This proof-of-concept study suggests that
nighttime administration of delayed-release
prednisone provides better asthma symptom
control compared with morning administration
of conventional immediate-release prednisone.
Timed delivery of prednisone during the peak
inflammatory period (early morning sleeping
hours) may be the most efficacious time to
administer exogenous glucocorticoids to
patients with nocturnal asthma.
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